Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults
British Journal of Haematology · 2026-11 · 209 (5) · 2168-2179
DOI: 10.1111/bjh.70818 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 04.09.2026. Verfasst von Jia Li und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Thrombocythemia, Essential. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents.
Abstract (Originalsprache)
Essential thrombocythaemia (ET) in adolescents and young adults (AYA, 15–39 years) is a distinct entity with an incompletely defined prognosis. In this multicentre retrospective study, 1728 ET patients from 29 centres across China were stratified into AYA ( n = 328) and non‐AYA (≥40 years, n = 1400) cohorts. We compared their clinical profiles, genomic landscapes, long‐term outcomes and risk factors for progression to post‐ET myelofibrosis (MF). AYA patients had fewer cardiovascular risks and lower thrombosis rates, but higher rates of extreme thrombocytosis. Molecularly, AYA patients were enriched for calreticulin ( CALR ) mutations, whereas Janus kinase 2 ( JAK2 ) predominated in older patients. The burden of non‐driver mutations ( tet methylcytosine dioxygenase 2 [ TET2 ], DNA methyltransferase 3A [ DNMT3A ], ASXL transcriptional regulator 1 [ ASXL1 ], SH2‑B adaptor protein 3 [ SH2B3 ]) was lower in AYA patients. Consequently, AYA patients achieved superior long‐term outcomes across all key survival endpoints, including overall, myelofibrosis‐free and leukaemia‐free survival. Analysis of post‐ET MF progression risks identified age‐specific patterns: CALR mutations are enriched in younger patients and show an age‐specific association with MF progression. AYA‐ET constitutes a unique clinicomolecular subtype with a favourable prognosis, supporting age‐stratified management. The enrichment of CALR mutations and their specific link to MF progression in young patients underscore the urgent need for targeted therapies against CALR ‐mutant clones.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Haematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Department of Haematology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
- Department of Haematology, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji, Zhejiang, China.
- Department of Haematology, Xiangshan First People's Hospital Medical and Health Group, Xiangshan, Zhejiang, China.
- Department of Hematopathology, Yangming Hospital, The Affiliated Hospital of Ningbo University (Yuyao People's Hospital), Yuyao, Zhejiang, China.
ORCID-Profile: Jia Li, Binbin Lai, Xiaojing Bao, Gang Zhang, Ying Lu, Weiying Feng, Meiwei Hu, Hongyan Tong, Jie Jin, Jian Huang
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
Zitieren
APA
Li, J., Wen, B., Yang, X., Qian, H., Lai, B., Yan, X., Bao, X., Zhou, M., Huang, Z., Xia, Y., Huang, L., Zhang, G., Zhu, F., Zhang, L., Shao, Y., Yao, G., Lu, Y., Han, Y., He, M., …, & Huang, J. (2026). Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults. British Journal of Haematology, 209(5), 2168-2179. https://doi.org/10.1111/bjh.70818
Vancouver
Li J, Wen B, Yang X, Qian H, Lai B, Yan X, et al. Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults. British Journal of Haematology. 2026;209(5):2168-2179. doi:10.1111/bjh.70818
BibTeX
@article{Li2026,
author = {Li, Jia and Wen, Bingbing and Yang, Xiudi and Qian, Honglan and Lai, Binbin and Yan, Xiao and Bao, Xiaojing and Zhou, Mei and Huang, Zhaohao and Xia, Yongming and Huang, Li and Zhang, Gang and Zhu, Feng and Zhang, Li and Shao, Yanping and Yao, Guoli and Lu, Ying and Han, Yanxia and He, Muqing and Cao, Dan and Lei, Huyi and Tang, Qinli and Chen, Yu and Feng, Weiying and Hu, Meiwei and Wang, Lifeng and Ge, Hangping and Lang, Xianghua and Cao, Lihong and Chen, Sai and Zhou, Hui and Zhang, Huiqi and Zhou, Xiujie and Tong, Hongyan and Jin, Jie and Huang, Jian},
title = {Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {5},
pages = {2168--2179},
doi = {10.1111/bjh.70818}
}
EUVIMED